Live from the NIH registry
Studies recruiting near Killeen right now
Top 25 of 105 recruiting studies, sorted by proximity — each links to its official registry page
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Heart Failure (HF)
N/A
Interventional 420 participants sought
Baylor Scott & White Research Institute — Temple, Texas (22.9 mi)
· Sponsor: Aventusoft, LLC.
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
Colorectal Adenocarcinoma, Stage I Colorectal Cancer AJCC v8
N/A
Observational 1,000 participants sought
Baylor Scott & White Research Institute — Temple, Texas (22.9 mi)
· Sponsor: M.D. Anderson Cancer Center
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
Type 2 Diabetes, Cortisol Excess
Phase 2
Interventional 1,500 participants sought
Radiance Clinical Research — Lampasas, Texas (26.8 mi)
· Sponsor: Sparrow Pharmaceuticals
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm
Phase 2
Interventional 70 participants sought
Scott and White Memorial Hospital — Temple, Texas (22.9 mi)
· Sponsor: National Cancer Institute (NCI)
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Pulmonary Disease, Chronic Obstructive
Phase 3
Interventional 960 participants sought
GSK Investigational Site — Lampasas, Texas (26.8 mi)
· Sponsor: GlaxoSmithKline
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Cancer, Metastatic, Cancer
N/A
Observational 50,000 participants sought
Massive Bio SYNERGY-AI site — Temple, Texas (22.9 mi)
· Sponsor: Massive Bio, Inc.
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Phase 2
Interventional 111 participants sought
Scott and White Memorial Hospital — Temple, Texas (22.9 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
High Grade Osteosarcoma, Localized Osteosarcoma
Phase 2, Phase 3
Interventional 1,122 participants sought
Scott and White Memorial Hospital — Temple, Texas (22.9 mi)
· Sponsor: National Cancer Institute (NCI)
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Heart Failure NYHA Class II, Heart Failure NYHA Class III
N/A
Interventional 1,750 participants sought
Baylor - Temple — Temple, Texas (22.9 mi)
· Sponsor: Endotronix, Inc.
Alleviant ALLAY-HFrEF Study
Heart Failure
N/A
Interventional 350 participants sought
Baylor Scott & White - Temple — Temple, Texas (22.9 mi)
· Sponsor: Alleviant Medical, Inc.
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Phase 1, Phase 2
Interventional 884 participants sought
USOR Texas Oncology Gulf Coast — Woodland, Texas (14.7 mi)
· Sponsor: Genmab
Trauma BPE Prolonged Exposure Therapy for Injured Individuals Admitted to a Level I Trauma Center
Traumatic Injury, PTSD
N/A
Interventional 300 participants sought
Baylor Scott & White Medical Center - Temple — Temple, Texas (22.9 mi)
· Sponsor: Baylor Research Institute
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Phase 2
Interventional 130 participants sought
Baylor Scott & White Health — Temple, Texas (22.9 mi)
· Sponsor: Hoffmann-La Roche
Treatment of Chronic Anger and Aggression Following Military-Related Betrayal
Anger Problems, Aggression
N/A
Interventional 40 participants sought
Carl R. Darnall Army Medical Center (CRDAMC) at Fort Cavazos — Fort Cavazos, Texas (4.9 mi)
· Sponsor: The University of Texas Health Science Center at San Antonio
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
Phase 3
Interventional 600 participants sought
Baylor Scott and White Medical Center — Temple, Texas (22.9 mi)
· Sponsor: Hoffmann-La Roche
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Cancer, Immunotherapy
N/A
Observational 2,000 participants sought
Baylor Scott and White Biorepository — Temple, Texas (22.9 mi)
· Sponsor: Elephas
Combining Stellate Ganglion Block With Prolonged Exposure for PTSD
Stress Disorders, Post-Traumatic
Phase 2
Interventional 140 participants sought
Carl R. Darnall Army Medical Center — Fort Hood, Texas (12.5 mi)
· Sponsor: The University of Texas Health Science Center at San Antonio
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
Asthma
Phase 3
Interventional 231 participants sought
Research Site — Temple, Texas (22.9 mi)
· Sponsor: AstraZeneca
Project: Every Child for Younger Patients With Cancer
Adrenal Gland Pheochromocytoma, Carcinoma In Situ
N/A
Observational 75,000 participants sought
Scott and White Memorial Hospital — Temple, Texas (22.9 mi)
· Sponsor: Children's Oncology Group
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Peripheral T Cell Lymphoma
Phase 3
Interventional 504 participants sought
Baylor Scott & White Medical Center - Temple — Temple, Texas (22.9 mi)
· Sponsor: Acrotech Biopharma Inc.
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC)
Phase 3
Interventional 1,040 participants sought
Scott and White Memorial Hospital — Temple, Texas (22.9 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Phase 2
Interventional 48 participants sought
Scott and White Memorial Hospital — Temple, Texas (22.9 mi)
· Sponsor: National Cancer Institute (NCI)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
Baylor Scott and White Medical Center — Temple, Texas (22.9 mi)
· Sponsor: Relay Therapeutics, Inc.
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Neutropenia
Phase 3
Interventional 176 participants sought
Sarah Cannon Research Institute — Woodland, Texas (14.7 mi)
· Sponsor: X4 Pharmaceuticals
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Stage III Colon Cancer
Phase 2, Phase 3
Interventional 1,912 participants sought
Scott and White Memorial Hospital — Temple, Texas (22.9 mi)
· Sponsor: NRG Oncology